ArticleObesity surgery2026
Type 2 Diabetes Relapse after Roux-en-Y Gastric Bypass and Sleeve Gastrectomy: A Systematic Review and Meta-Analysis.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionType 2 diabetes mellitus (T2DM) remission after bariatric surgery may not be durable, and relapse after initial remission is an increasingly important outcome. This systematic review and meta-analysis compared the risk of T2DM relapse after Roux-en-Y gastric bypass (RYGB) versus sleeve gastrectomy (SG) in patients with obesity and T2DM who achieved postoperative remission.
methodsPubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to April 20, 2026. Eligible studies included adults with obesity and preoperative T2DM who underwent primary RYGB or SG and reported T2DM relapse after remission. Hazard ratios (HRs) and odds ratios (ORs) were pooled separately using random-effects models. Study quality was assessed using the Newcastle-Ottawa Scale or Cochrane risk of bias tool.
resultsNine studies comprising 11 cohorts and 24,228 patients were included; 9,674 underwent SG and 14,554 underwent RYGB. The mean age was 49.5 years, 31.4% were male, the mean BMI was 47.7 kg/m², and the mean T2DM duration was 5.7 years. Compared with SG, RYGB was associated with a significantly lower risk of T2DM relapse in HR-based analyses (HR, 0.67; 95% CI, 0.59-0.76; P < 0.0001; I² = 23.1%) and OR-based analyses (OR, 0.63; 95% CI, 0.52-0.76; P < 0.0001; I² = 0%). Subgroup analysis, sensitivity analysis, and publication-bias analysis supported the robustness of the findings.
conclusionsThis systematic review and meta-analysis suggests that RYGB was associated with a lower risk of T2DM relapse after initial remission than SG. However, given the predominantly retrospective nature of the available evidence, these findings should be interpreted cautiously and require confirmation in well-designed prospective studies.
Indexed as
Identifiers
42945021What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.